Current evidence does not establish that GLP-1 medications directly cause clinical depression, and some research has suggested potential mood benefits in certain populations
For people with MTHFR mutations, supplementation with methylfolate will be more beneficial than folic acid, as they might have a reduced capacity to turn folic acid into methylfolate
For this reason, individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use these therapies

Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations

Beginning July 1, eligible Medicare beneficiaries with Part D prescription coverage may be able to receive certain GLP-1 medications for $50 per month
Since everyone biology varies, trying both peptides at different times can help identify which works better for a specific person